Surrozen (SRZN) Other Non-Current Liabilities (2021 - 2026)
Surrozen (SRZN) posted quarterly Other Non-Current Liabilities of $235.5 million for Q1 2026, up 455.16% year-over-year from $42.4 million in Q1 2025, and up 48.44% quarter-over-quarter from $158.7 million in Q4 2025.
Surrozen (SRZN) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Surrozen's Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $235.5 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 455.16% year-over-year to $235.5 million; the TTM figure through Mar 2026 stood at $235.5 million (up 455.16% YoY), while the FY2025 annual figure was $158.7 million, up 183.87% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $235.5 million, up from $158.7 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $235.5 million in Q1 2026, with the low at $115000.0 in Q4 2023.
- The 5-year median for Other Non-Current Liabilities is $1.8 million (2022), against an average of $38.5 million.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities tumbled 96.07% in 2022, then soared 48501.74% in 2024.
- Surrozen's Other Non-Current Liabilities stood at $326000.0 in 2022, then slumped by 64.72% to $115000.0 in 2023, then jumped by 48501.74% to $55.9 million in 2024, then surged by 183.87% to $158.7 million in 2025, then soared by 48.44% to $235.5 million in 2026.
- Business Quant data shows SRZN's Other Non-Current Liabilities at $235.5 million in Q1 2026, $158.7 million in Q4 2025, and $53.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 196.27 Mn |
| Mar 31, 2026 | 235.52 Mn |
| Dec 31, 2025 | 158.66 Mn |
| Sep 30, 2025 | 53.54 Mn |
| Jun 30, 2025 | 32.62 Mn |
| Mar 31, 2025 | 42.42 Mn |
| Dec 31, 2024 | 55.89 Mn |
| Sep 30, 2024 | 36.21 Mn |
| Jun 30, 2024 | 33.03 Mn |
| Mar 31, 2024 | 178,000.00 |
| Dec 31, 2023 | 115,000.00 |
| Sep 30, 2023 | 243,000.00 |
| Jun 30, 2023 | 326,000.00 |
| Mar 31, 2023 | 591,000.00 |
| Dec 31, 2022 | 326,000.00 |
| Sep 30, 2022 | 1.33 Mn |
| Jun 30, 2022 | 1.38 Mn |
| Mar 31, 2022 | 1.80 Mn |
| Dec 31, 2021 | 8.30 Mn |
| Sep 30, 2021 | 8.31 Mn |